Literature DB >> 7800043

Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins.

W Seufert1, B Futcher, S Jentsch.   

Abstract

Cell cycle progression in eukaryotes is controlled by the p34cdc2/CDC28 protein kinase and its short-lived, phase-specific regulatory subunits called cyclins. In Xenopus oocytes, degradation of M-phase (B-type) cyclins is required for exit from mitosis and is mediated by the ubiquitin-dependent proteolytic system. Here we show that B-type-cyclin degradation in yeast involves an essential nuclear ubiquitin-conjugating enzyme, UBC9. Repression of UBC9 synthesis prevents cell cycle progression at the G2 or early M phase, causing the accumulation of large budded cells with a single nucleus, a short spindle and replicated DNA. In ubc9 mutants both CLB5, an S-phase cyclin, and CLB2, an M-phase cyclin, are stabilized. In wild-type cells the CLB5 protein is unstable throughout the cell cycle, whereas CLB2 turnover occurs only at a specific cell-cycle stage. Thus distinct degradation signals or regulated interaction with the ubiquitin-protein ligase system may determine the cell-cycle specificity of cyclin proteolysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7800043     DOI: 10.1038/373078a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  176 in total

Review 1.  Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha.

Authors:  R T Hay; L Vuillard; J M Desterro; M S Rodriguez
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-09-29       Impact factor: 6.237

2.  The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells.

Authors:  F Giorgino; O de Robertis; L Laviola; C Montrone; S Perrini; K C McCowen; R J Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Testing cyclin specificity in the exit from mitosis.

Authors:  M D Jacobson; S Gray; M Yuste-Rojas; F R Cross
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

4.  Backbone resonance assignments of human UBC9.

Authors:  Q Liu; B Shen; D J Chen; Y Chen
Journal:  J Biomol NMR       Date:  1999-01       Impact factor: 2.835

5.  The yeast C-type cyclin Ctk2p is phosphorylated and rapidly degraded by the ubiquitin-proteasome pathway.

Authors:  G Hautbergue; V Goguel
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

6.  Creation of a pluripotent ubiquitin-conjugating enzyme.

Authors:  C Ptak; C Gwozd; J T Huzil; T J Gwozd; G Garen; M J Ellison
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

Review 7.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

8.  Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins.

Authors:  T Yasugi; M Vidal; H Sakai; P M Howley; J D Benson
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

9.  Cyclin regulation by the s phase checkpoint.

Authors:  Gloria Palou; Roger Palou; Angel Guerra-Moreno; Alba Duch; Anna Travesa; David G Quintana
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

Review 10.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.